Cellectis S.A.

Some of the best links we picked up around the internet

CMN Weekly (28 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 28, 2025

Some of the best links we picked up around the internet

CMN Weekly (13 December 2024) - Your Weekly CRISPR...

CMN Weekly

Dec. 13, 2024

Some of the best links we picked up around the internet

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

TALEN-Engineered CAR-T Cells Deliver Precision...

CMN Interview

Sep. 30, 2024

Dual CAR-T cells incorporating an IF/THEN logic-gated system show enhanced anti-tumour cytotoxicity and reduced off-tumour effects in mouse models....

CMN Weekly (9 August 2024) - Your Weekly CRISPR...

CMN Weekly

Aug. 9, 2024

Some of the best links we picked up around the internet

CMN Weekly (2 August 2024) - Your Weekly CRISPR...

CMN Weekly

Aug. 2, 2024

Some of the best links we picked up around the internet

CMN Weekly (14 June 2024) - Your Weekly CRISPR...

CMN Weekly

Jun. 14, 2024

Some of the best links we picked up around the internet

Cellectis S.A.

Blastic Plasmacytoid Dendritic Cell Neoplasm, BPDCN, (NCT03203369)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

B-Cell Non-Hodgkin Lymphoma, NHL, (NCT05607420)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukaemia, AML, (2018-001018-14)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Acute Myeloid Leukaemia, AML, (NCT04106076)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia, B-ALL, (NCT04150497)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Acute Myeloid Leukaemia, AML, (NCT03190278)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Multiple Myeloma, MM, (NCT04142619)
Sponsors:
Cellectis S.A.

IND Enabling

Phase I

Phase II

Phase III